CETUKSIMABA in English translation

• cetuximab

Examples of using Cetuksimaba in Slovenian and their translations into English

Najnovejši podatki so pokazali, da imajo bolniki z metastatskim kolorektalnim rakom z nemutiranim tipom KRAS pomembno večjo možnost, da jim zdravljenja s cetuksimabom ali kombinacijo cetuksimaba in kemoterapije prinaša koristi.
Recent data demonstrate that patients with KRAS wild-type metastatic colorectal cancer have a significantly higher chance to benefit from treatment with cetuximab or a combination of cetuximab and chemotherapy.

s kombinacijo oksaliplatina in fluoropirimidina, primerjali kombinacijo cetuksimaba in irinotekana(648 bolnikov)
fluoropyrimidine for metastatic disease compared the combination of cetuximab and irinotecan(648 patients)

V tej randomizirani študiji so pri bolnikih z metastatskim kolorektalnim rakom po neuspešnem zdravljenju metastatske bolezni z irinotekanom kot zadnjem zdravljenjem pred vstopom v študijo primerjali kombinacijo cetuksimaba in irinotekana(218 bolnikov)
This randomised study in patients with metastatic colorectal cancer after failure of irinotecan-based treatment for metastatic disease as the last treatment before study entry compared the combination of cetuximab and irinotecan(218 patients)

Tako se je izkazalo, da v nasprotju z našimi izkušnjami z bolj običajno citotoksično kemoterapijo hkratna uporaba cetuksimaba in sevanja morda ne bo škodljivo vplivala na toksičnost, povezano s sevanjem, znotraj obsega sevanja.
And so, it appeared that, unlike our experience with more usual cytotoxic chemotherapy, the simultaneous use of cetuximab and radiation may not have any deleterious effect on radiation-related toxicity within the radiation volume.

Cetuksimaba niso raziskovali pri bolnikih, ki so imeli katerega od naslednjih laboratorijskih parametrov:• hemoglobin< 9 g/ dl• število levkocitov< 3. 000/ mm³• absolutno število nevtrofilcev<
Cetuximab has not been studied in patients presenting with one or more of the following laboratory parameters:• haemoglobin<

danke kažejo, da je uporaba monoklonskih protiteles proti EGFR, panitumumaba in cetuksimaba, v kombinaciji s kemoterapijo
in patients with mCRC suggest that the use of anti-EGFR monoclonal antibodies panitumumab and cetuximab, respectively, in combination with bevacizumab

Ta randomizirana študija pri bolnikih z metastatskim kolorektalnim rakom, ki še niso bili zdravljeni zaradii metastatske bolezni, je primerjala kombinacijo cetuksimaba in oksaliplatina ter infudiranega 5- fluorouracila/ folinske kisline(5- FU/ FA)(169 bolnikov)
This randomised study in patients with metastatic colorectal cancer who had not received prior treatment for metastatic disease compared the combination of cetuximab and oxaliplatin plus infusional 5-fluorouracil/ folinic acid(5-FU/ FA)(169 patients)

bi bolnikom z metastatskim kolorektalnim rakom in z aktivacijskimi mutacijami RAS zdravljenje s cetuksimabom ali kombinacijo cetuksimaba in kemoterapije koristilo, v primeru, da je šlo za dodatno zdravilo k FOLFOX4, pa so se pokazali pomembni negativni učinki na čas preživetja brez napredovanja bolezni(PFS).
activating RAS mutations are highly unlikely to benefit from treatment with cetuximab or a combination of cetuximab and chemotherapy and as add-on to FOLFOX4 a significant negative effect on progression-free survival time(PFS) was shown.

vratu, ki pred tem niso prejemali kemoterapije za to bolezen, so primerjali kombinacijo cetuksimaba in cisplatina ali karboplatina skupaj z 5- fluorouracilom v infuziji(222 bolnikov)
neck who had not received prior chemotherapy for this disease compared the combination of cetuximab and cisplatin or carboplatin plus infusional 5-fluorouracil(222 patients)

Primarni neželeni učinki cetuksimaba so kožne reakcije,
The primary undesirable effects of cetuximab are skin reactions,

Glavni neželeni učinki cetuksimaba so kožne reakcije,
The main undesirable effects of cetuximab are skin reactions,

Ml vsebuje 2 mg cetuksimaba.
Ml contains 2 mg cetuximab.

En ml raztopine za infundiranje vsebuje 5 mg cetuksimaba.
Each mL of solution for infusion contains 5 mg cetuximab.

Podatkov o učinku cetuksimaba na plodnost pri ljudeh ni.
There are no data on the effect of cetuximab on human fertility.

Vsak ml raztopine za infundiranje vsebuje 2 mg cetuksimaba.
Each ml of solution for infusion contains 2 mg cetuximab.

Študije toksičnosti pri sočasni uporabi cetuksimaba in kemoterapevtikov niso bile opravljene.
Toxicity studies with co-administration of cetuximab and chemotherapeutic agents have not been performed.

Glavni neželeni učinek cetuksimaba so kožne reakcije, ki lahko postanejo resne,
Main adverse reactions of cetuximab are skin reactions which may become severe,

Navadno nastopijo v roku ene ure od prve infuzije cetuksimaba, vendar se lahko pojavijo tudi po več urah
They usually develop during or within 1 hour of the initial cetuximab infusion, but may occur after several hours

se pojavijo časovno zelo povezano zlasti s prvim infundiranjem cetuksimaba.
dyspnoea that occur in a close temporal relationship mainly to the first cetuximab infusion.

Serumske koncentracije cetuksimaba so dosegle stalno raven po treh tednih monoterapije s cetuksimabom.
Cetuximab serum concentrations reached stable levels after three weeks of cetuximab monotherapy.